MTOR and prostate carcinoma: miR-218 reduces VEGF expression in prostate cancer by acting on the mTOR component RICTOR (rapamycin-insensitive companion of mammalian target of rapamycin) and by blocking the RICTOR/mTOR/HIF-1/VEGF signaling pathway [110].